Simplify Logo

Full-Time

Research Associate I

Posted on 8/26/2024

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Biotechnology
Healthcare

Compensation Overview

$75k - $91kAnnually

Entry

San Bruno, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Inventory Management
Requirements
  • B.S. in scientific discipline with 0-2 years of related experience and understanding of medicinal chemistry.
  • Has experience maintaining lab equipment along with inventory levels of supplies.
  • Proven analytical and problem-solving skills, with the ability to critically evaluate and interpret experimental data.
  • Understands and acts on detailed instructions while also demonstrating initiative.
Responsibilities
  • Under supervision design and synthesize next generation compounds by application of medicinal chemistry knowledge to the analysis of potency, DMPK, and off-target selectivity data.
  • Accomplish the synthesis of enough designed target molecules and key intermediates with high productivity for biological, DMPK and in vivo studies.
  • Summarize/interpret data and present findings in research meetings.
  • Maintain detailed experimental records; Documents of experiments in the electronic lab notebook should be in full compliance with the guidelines established within the company and chemistry department.
  • Use software infrastructure including Scifinder, ChemCart,,Spotfire, Stardrop and Moe to carry out daily research activities efficiently.
  • Help maintain research lab productivity by adhering to outlined group responsibilities and safety procedures. Manage the medicinal chemistry group inventory; track and order the supply weekly.
  • Attend and present posters at scientific /technical conferences; Contribute to scientific paper and /or patents.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE